Navigation Links
Lightwave Logic, Inc. Announces the Addition of Anthony J. Cocuzza, PhD to its Technology Team

NEWARK, Del., Feb. 19 /PRNewswire-FirstCall/ -- Lightwave Logic, Inc. (OTC Bulletin Board: LWLG - News;, a technology company focused on the development of electro-optic polymer materials for applications in high speed fiber-optic telecommunications and optical computing, announced today the addition of Anthony J. Cocuzza, PhD to our technology team. Dr. Cocuzza worked for 30 years in medicinal chemistry and brings a highly developed set of synthetic and analytical skills to Lightwave Logic.

A graduate of Princeton, Dr. Cocuzza spent 24 years with DuPont engaged in R&D in corporate R&D and with DuPont's joint venture with Merck. He retired in 2008 from Bristol-Meyers Squib. Cocuzza has contributed to programs in many areas of medicinal and biological chemistry. David Eaton, CTO of Lightwave commented: "We are extremely happy to attract a scientist with Dr. Cocuzza's talents. His capabilities are an excellent match to our needs. We expect he will be able to contribute strongly to our efforts to expand our molecular materials base."

Jim Marcelli, CEO of Lightwave stated, "I'm very excited to have Dr. Cocuzza join the Lightwave family. Tony's experience in organic synthesis will help to streamline our preparation and scale-up of our Perkinamine family of materials."

About Lightwave Logic, Inc.

Lightwave Logic, Inc. is a development stage company, moving toward prototype demonstration and commercialization of its high-activity, high-stability organic polymers for applications in electro-optical device markets. Electro-optical devices convert data from electric signals into optical signals for use in high-speed fiber-optic telecommunications systems and optical computers. Please visit the Company's website,, for more information.

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.

SOURCE Lightwave Logic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hologic, Inc. to Host Investor Reception at the RSNA Trade Show
2. ETEX Launches Innovative Osteoinductive Orthobiologic, EquivaBone(TM)
3. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
4. Hologic, Inc. to Release Second Quarter Fiscal 2008 Operating Results Thursday, May 1st Before Market Opens
5. Hologic, Inc. to Release First Quarter Fiscal 2008 Operating Results Thursday, January 31st Before Market Opens
6. Psychemedics Corporation Announces 2008 Year End Results
7. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
8. Amicus Therapeutics Announces Change to Board of Directors
9. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2008 Earnings Release Conference Call Webcast
10. Obio Pharmaceutical Announces Product Growth Strategy
11. Pressure BioSciences, Inc. Announces Completion of Private Placement
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:5/12/2016)... , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):